GlassScriptPhysician profile
Jason Cutler
NPI 1154716991
$1,884.63
in general payments reported to CMS, 2019-2025
23 companies · $97.56 in 2025
The $97.56 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $180 · 2021: $806 · 2022: $751 · 2023: $23.10 · 2024: $27.37 · 2025: $97.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $477.67 | 2020-2022 | |
| Abbott Laboratories | $205.42 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $194.08 | 2020-2022 | |
| Lilly USA, LLC | $192.51 | 2021-2022 | |
| Pfizer INC. | $111.64 | 2021 | |
| Insulet Corporation | $110.71 | 2021 | |
| Medtronic, INC. | $75.96 | 2021-2025 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $64.34 | 2022-2024 | |
| Corcept Therapeutics | $61.40 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $44.33 | 2021 | |
| Dexcom, INC. | $43.77 | 2022 | |
| Mannkind Corporation | $35.17 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $34.31 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $33.00 | 2021-2022 | |
| Amryt Pharma Holdings LTD | $28.54 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $27.11 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $26.22 | 2020 | |
| Abbvie INC. | $23.10 | 2023 | Synthroid |
| Amneal Pharmaceuticals LLC | $22.35 | 2022 | |
| Ibsa Pharma INC. | $21.74 | 2021 | |
| Merck Sharp & Dohme LLC | $20.88 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $15.67 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Cutler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.